Factors such as rising incidence of diabetes & associated wounds, growing aging population, rising incidence of burn injuries, and growing awareness programs for wound care treatment and management are driving the growth of the wound debridement market.
Gels accounted for the largest share of the wound debridement market in 2017.
Based on products, the wound debridement market is segmented into gels, ointments & creams, surgical devices, ultrasound devices, mechanical debridement pads, medical gauzes, and other wound debridement products. Of all these product segments, gels accounted for the largest share of the market in 2017. The large share of this market segment can primarily be attributed to the wide range of advantages associated with the use of gels. Gels are safe and effective, do not cause inflammation, and remove necrotic tissue from wounds.
The hospitals segment is estimated to grow at the highest CAGR during the forecast period.
Based on end user, the wound debridement market has been segmented into hospitals, clinics, and other end users. The hospitals segment is estimated to grow at the highest CAGR during the forecast period. The availability of infrastructure and the presence of skilled professionals in hospitals are the major driving factors for this segment.
North America commanded the largest share of the market in 2017.
Based on region, the wound debridement market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2017, North America accounted for the largest share of the wound debridement market. The increasing incidence of venous leg ulcers and diabetic foot ulcers as well as the presence of all the major players in this region are the major factors supporting the growth of the wound debridement market in North America.
The major players in the wound debridement market include Smith & Nephew (UK), B. Braun Melsungen AG (Germany), Coloplast (Denmark), Misonix (US), ConvaTec (UK), Lohmann & Rauscher (Germany), DeRoyal Industries (US), Medline Industries (US), Mölnlycke Health Care AB (Sweden), and Integra LifeSciences (US).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
